Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMounjaro (tirzepatide) for weight loss follows a fixed titration schedule across six strengths — 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg — each given as a once-weekly injection, with dose increases guided by your prescriber roughly every four weeks. The schedule exists to reduce side effects, not to delay results. These are prescription-only medicines: a GPhC-registered prescriber reviews your full clinical picture before any dose is issued or changed. Understanding how the tirzepatide dosage for weight loss works in practice helps you know what to expect at each stage of treatment.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Every person starting Mounjaro begins on the 2.5 mg pen, no matter what their prescriber expects the eventual maintenance dose to be. That isn't a low-ambition choice. Tirzepatide slows gastric emptying significantly, and starting at full strength would overwhelm most people's digestive system. The 2.5 mg month is about building tolerance: nausea, bloating and loose stools are commonest in the first few weeks after starting or increasing, and they almost always settle. Your prescriber will ask how you've got on before moving you forward. If side effects were significant, they may recommend staying at 2.5 mg for a second four-week cycle. There is no clinical benefit from rushing the titration; the injection dosage schedule is designed so that the weight loss arrives steadily rather than front-loaded. Most people notice appetite changes even at this starting strength, though the effect deepens considerably at higher doses.
After the first four weeks, your prescriber increases the dose to 5 mg. If that is well tolerated, the next review moves you to 7.5 mg, then 10 mg, then 12.5 mg, each step spaced roughly one month apart. In practice, this four-month window is where most of the visible change happens. Appetite suppression becomes more pronounced, satiety signals arrive earlier in a meal, and weight reduction typically accelerates through this range. A useful way to think about it: the lower doses are the runway; the middle doses are where you reach cruising altitude. Not everyone needs to climb all the way to 15 mg. Some people find their appetite well controlled and side effects minimal at 7.5 mg or 10 mg and, with their prescriber's agreement, stay there. The 5 mg dose is often the first point where people notice the medicine doing something distinct from the starter phase, worth knowing so you're not caught off guard. The escalation period is also the right time to build the dietary habits that will support you long-term, since the appetite window the medicine opens is a tool, not a permanent override.
For those who reach it, 15 mg is the maximum licensed dose for weight management and the dose studied most extensively in clinical trials. In the SURMOUNT-1 trial (2,539 adults with obesity, 72 weeks) participants randomised to 15 mg saw average body-weight reductions of around 20–21%, as published in the New England Journal of Medicine. Those are group averages; individual results vary depending on starting weight, adherence, diet and activity. The maintenance phase is ongoing clinical work, not a finishing line. At every repeat order, a prescriber reviews your progress. If after six months at your highest tolerated dose the 5% threshold hasn't been met, NICE TA1026 guidance says continuing treatment should be reconsidered. That review protects you from months of a medicine that isn't helping. Some people do reach a plateau; the clinical conversation at that point is about whether to hold, adjust or stop. The concept of a "golden dose" is really just shorthand for the highest strength at which you tolerate treatment well and continue to see benefit, it's personal, not universal.
The dose you're on directly affects what you pay. Higher-strength pens carry higher list prices, and since Eli Lilly adjusted UK pricing in September 2025, the gap between entry and maximum strength is considerable, reported private prices range roughly £149–£375 a month by dose and provider. A plain chart of that can make treatment look expensive at the top end, which is why it's worth reading a full breakdown of what those prices include before comparing figures. When you order through a regulated pharmacy like ours, what arrives is a pre-filled KwikPen in plain, unbranded packaging, with a DPD tracking link so you know exactly when it'll be at your door. The pen contains four doses (four weeks of treatment) and is refrigerated until you're ready to use it. The full Mounjaro overview covers storage and handling in more detail. One thing that catches people out: you can't simply request a higher dose because a lower one is out of stock or because you've decided you're ready. Evidence of your current dose and clinical review are required before any increase. It sounds administrative, but it's the safeguard that makes the titration schedule safe rather than theoretical. If you're weighing up treatment options more broadly, our treatment overview sets out what's available and what the differences are.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.